{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:44:04Z","timestamp":1776545044828,"version":"3.51.2"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crphar.2024.100179","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T03:25:50Z","timestamp":1710386750000},"page":"100179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition"],"prefix":"10.1016","volume":"6","author":[{"given":"Hisham A.","family":"Badreldin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Alsuhebany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmajeed M.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Aldoughaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Alqifari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-0941","authenticated-orcid":false,"given":"Lama","family":"Alfehaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.crphar.2024.100179_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11216314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and Arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J. Clin. Med."},{"issue":"13","key":"10.1016\/j.crphar.2024.100179_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant Use: a Practical Guide to Common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.crphar.2024.100179_bib3","first-page":"175","article-title":"The evolution of anticoagulant therapy","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"13","key":"10.1016\/j.crphar.2024.100179_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.crphar.2024.100179_bib5","article-title":"Factor XI, a potential target for anticoagulation therapy for venous thromboembolism","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.crphar.2024.100179_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.crphar.2024.100179_bib7","series-title":"(Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI\/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker) Oral Presentation at the American Heart Association Scientific Sessions. 2023","author":"Ruff","year":"2013"},{"issue":"2","key":"10.1016\/j.crphar.2024.100179_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.crphar.2024.100179_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/hae.12628","article-title":"Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single center","volume":"21","author":"Santoro","year":"2015","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.crphar.2024.100179_bib10","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.thromres.2014.03.018","article-title":"Physiologic activities of the contact activation system","volume":"133","author":"Schmaier","year":"2014","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.crphar.2024.100179_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41598-021-81268-7","article-title":"Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro","volume":"11","author":"Shi","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.crphar.2024.100179_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a Quick Guide","volume":"12","author":"Sikorska","year":"2017","journal-title":"Eur. Cardiol."},{"issue":"15","key":"10.1016\/j.crphar.2024.100179_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12154890","article-title":"Persistently high levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"12","author":"Spiezia","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.crphar.2024.100179_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis Induced by Artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"7","key":"10.1016\/j.crphar.2024.100179_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"ANT-005 TKA Investigators. Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.crphar.2024.100179_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why factor XI deficiency is a clinical concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert Rev. Hematol."},{"issue":"2","key":"10.1016\/j.crphar.2024.100179_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257124000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257124000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T22:45:54Z","timestamp":1718577954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257124000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"alternative-id":["S2590257124000063"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2024.100179","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2024.100179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100179"}}